Trial
NCT04185311
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Anatomic Stage 0 Breast Cancer AJCC v8
Intervention
Ipilimumab
Why stopped
enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-15